Author Details

Капланов, Камиль Даниялович

Issue	Section	Title	File
Vol 10, No 4 (2008)	Articles	Rekomendatsii po obsledovaniyu i lecheniyu bol'nykh V-kletochnym khronicheskim limfoleykozom	() () () () () () ()
Vol 16, No 2 (2014)	Articles	The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma	() () () () () () ()
Vol 21, No 4 (2019)	CLINICAL ONCOLOGY	The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution	(Rus)
Vol 22, No 1 (2020)	CLINICAL ONCOLOGY	ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution	(Rus)
Vol 22, No 2 (2020)	Guidelines	Hodgkin's lymphoma	(Rus)
Vol 22, No 2 (2020)	Conference Proceedings	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic	(Rus)
Vol 22, No 2 (2020)	Conference Proceedings	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas	(Rus)
Vol 23, No 1 (2021)	CLINICAL ONCOLOGY	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas	(Rus)
Vol 23, No 2 (2021)	CLINICAL ONCOLOGY	The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review	(Rus)
Vol 23, No 3 (2021)	CLINICAL ONCOLOGY	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia	(Rus)

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register